- Home
- ATXS vs BNTC Comparison
ATXS vs BNTC Comparison
Compare ATXS & BNTC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ATXS
- BNTC
- Stock Information
- Founded
- ATXS 2008
- BNTC 1995
- Country
- ATXS United States
- BNTC United States
- Employees
- ATXS N/A
- BNTC N/A
- Industry
- ATXS Biotechnology: Pharmaceutical Preparations
- BNTC Biotechnology: Pharmaceutical Preparations
- Sector
- ATXS Health Care
- BNTC Health Care
- Exchange
- ATXS Nasdaq
- BNTC Nasdaq
- Market Cap
- ATXS 401.2M
- BNTC 335.5M
- IPO Year
- ATXS 2015
- BNTC N/A
- Fundamental
- Price
- ATXS $6.65
- BNTC $11.18
- Analyst Decision
- ATXS Strong Buy
- BNTC Strong Buy
- Analyst Count
- ATXS 7
- BNTC 6
- Target Price
- ATXS $32.43
- BNTC $23.83
- AVG Volume (30 Days)
- ATXS 304.1K
- BNTC 197.6K
- Earning Date
- ATXS 08-11-2025
- BNTC 05-14-2025
- Dividend Yield
- ATXS N/A
- BNTC N/A
- EPS Growth
- ATXS N/A
- BNTC N/A
- EPS
- ATXS N/A
- BNTC N/A
- Revenue
- ATXS N/A
- BNTC N/A
- Revenue This Year
- ATXS N/A
- BNTC N/A
- Revenue Next Year
- ATXS N/A
- BNTC N/A
- P/E Ratio
- ATXS N/A
- BNTC N/A
- Revenue Growth
- ATXS N/A
- BNTC N/A
- 52 Week Low
- ATXS $3.56
- BNTC $7.05
- 52 Week High
- ATXS $12.92
- BNTC $17.15
- Technical
- Relative Strength Index (RSI)
- ATXS 60.88
- BNTC 38.38
- Support Level
- ATXS $5.94
- BNTC $11.00
- Resistance Level
- ATXS $6.49
- BNTC $12.26
- Average True Range (ATR)
- ATXS 0.34
- BNTC 0.91
- MACD
- ATXS -0.00
- BNTC -0.05
- Stochastic Oscillator
- ATXS 74.74
- BNTC 5.77
About ATXS Astria Therapeutics Inc.
Astria Therapeutics Inc is a biopharmaceutical company engaged to bring life-changing therapies to patients and families affected by rare and niche allergic and immunological diseases. Its lead program, STAR-0215, is a monoclonal antibody inhibitor of plasma kallikrein in preclinical development for the treatment of hereditary angioedema. Their second product candidate is STAR-0310, a monoclonal antibody OX40 antagonist that is in preclinical development for the treatment of atopic dermatitis, or AD, an immune disorder associated with loss of skin barrier function and itching.
About BNTC Benitec Biopharma Inc.
Benitec Biopharma Inc is a clinical-stage biotechnology company focused on the advancement of novel genetic medicines. Its technology has the potential to provide a one-shot cure for a wide range of diseases that are addressed by strict ongoing treatment regimens or that have no effective treatment or only palliative care options. The Company is developing a silence and replace-based therapeutic (BB-301) for the treatment of Oculopharyngeal Muscular Dystrophy (OPMD), a chronic, life threatening genetic disorder.